Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response

NCT02720120 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02720120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02720120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Terminated
Start date
October 31, 2005
Completion date
February 28, 2013
Enrollment
175 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis